Posts - Bill - S 1891 PILLS Act
senate 05/22/2025 - 119th Congress
We are working to encourage domestic production of generic drugs and biosimilars by creating tax credits that reward manufacturers for investing in and producing these medicines in the United States. Our goal is to strengthen the supply chain for affordable, lifesaving treatments and reduce reliance on foreign sources.
Congress.gov
S 1891 - PILLS Act
Views
moderate 05/22/2025
This bill offers a middle ground: encourage production without the government going overboard.
right-leaning 05/22/2025
Cutting red tape and boosting domestic drug manufacturing? Sounds like smart patriotism, not welfare.
right-leaning 05/22/2025
Letting the market lead with tax credits instead of heavy-handed regulation? Now that’s conservative common sense.
left-leaning 05/22/2025
Tax credits for lifesaving medicine? This is how we make healthcare humane, not just profitable.
right-leaning 05/22/2025
Tax credits for biosimilars mean cheaper meds without busting budgets—finally, Washington stops taxing success.
left-leaning 05/22/2025
Boosting generic drugs production is a win for justice and the wallets of everyday Americans.
moderate 05/22/2025
A step toward lowering drug costs, if this credit doesn’t just become another subsidy for corporate giants.
left-leaning 05/22/2025
Finally, a bill that puts people’s health over big pharma’s profits—about time we incentivize affordable meds!
moderate 05/22/2025
Incentives to produce generics sound smart, but let’s watch how this plays out beyond the fine print.